NLRP3-IN-13
NLRP3-IN-13 (Compound C77 in reference patent) is a selective and potent NLRP3 inhibitor (IC50: 2.1 μM) . NLRP3-IN-13 inhibits NLRP3 andNLRC4 inflammasomes, and inhibits NLRP3-mediated IL-1β production. NLRP3-IN-13 also inhibits NLRP3 ATPase activity. NLRP3-IN-13 can be used in the research of neuroinflammatory disorders[1].
Product Specifications
CAS Number
1704638-35-6
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nlrp3-in-13.html
Purity
98.03
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1OC2=C(N1CC(NCC3=CN=CC(C4=CSC=C4)=C3)=O)C=CC=C2
Molecular Formula
C19H15N3O3S
Molecular Weight
365.41
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501
References & Citations
[1]Devita Robert, et al. Benzoxazolones as inhibitors of inflammasomes and their preparation. Patent. WO2022187804.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NLRP3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Von Willebrand Factor (3E2D10), CF740 conjugate, 0.1mg/mL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF740 conjugate, 0.1mg/mL
CD50 / ICAM3 (CG106), CF568 conjugate, 0.1mg/mL
Cytochrome C (CTC05), CF640R conjugate, 0.1mg/mL
CD8b, Mouse (H35-17.2), CF594 conjugate, 0.1mg/mL
